- Home
- GHY vs SGMO Comparison
GHY vs SGMO Comparison
Compare GHY & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHY
- SGMO
- Stock Information
- Founded
- GHY 2012
- SGMO 1995
- Country
- GHY United States
- SGMO United States
- Employees
- GHY N/A
- SGMO N/A
- Industry
- GHY Trusts Except Educational Religious and Charitable
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GHY Finance
- SGMO Health Care
- Exchange
- GHY Nasdaq
- SGMO Nasdaq
- Market Cap
- GHY 528.3M
- SGMO 256.6M
- IPO Year
- GHY N/A
- SGMO 2000
- Fundamental
- Price
- GHY $13.12
- SGMO $1.21
- Analyst Decision
- GHY
- SGMO Buy
- Analyst Count
- GHY 0
- SGMO 6
- Target Price
- GHY N/A
- SGMO $5.17
- AVG Volume (30 Days)
- GHY 184.8K
- SGMO 4.8M
- Earning Date
- GHY 01-01-0001
- SGMO 03-12-2025
- Dividend Yield
- GHY 10.58%
- SGMO N/A
- EPS Growth
- GHY N/A
- SGMO N/A
- EPS
- GHY N/A
- SGMO N/A
- Revenue
- GHY N/A
- SGMO $52,291,000.00
- Revenue This Year
- GHY N/A
- SGMO N/A
- Revenue Next Year
- GHY N/A
- SGMO $5.97
- P/E Ratio
- GHY N/A
- SGMO N/A
- Revenue Growth
- GHY N/A
- SGMO N/A
- 52 Week Low
- GHY $10.24
- SGMO $0.30
- 52 Week High
- GHY $11.92
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- GHY 55.61
- SGMO 40.95
- Support Level
- GHY $12.77
- SGMO $1.14
- Resistance Level
- GHY $13.45
- SGMO $1.29
- Average True Range (ATR)
- GHY 0.21
- SGMO 0.09
- MACD
- GHY 0.01
- SGMO 0.04
- Stochastic Oscillator
- GHY 53.33
- SGMO 54.17
About GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.